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Background. The progression of diabetic nephropathy is
closely related to disturbances in glomerular hemodynamics,
such as glomerular hypertension and/or hyperperfusion. The
aim of this study was to observe and to analyze glomerular
hemodynamics in rats with diabetes mellitus (DM) in vivo us-
ing confocal laser scan microscopy (CLSM). We also exam-
ined the effects of candesartan cilexetil (TCV-116), a selective
angiotensin II type 1 receptor blocker (ARB), on glomerular
hemodynamics in DM.
Methods. Munich-Wistar rats were divided into six groups: (1)
four-day control; (2) four-day DM; (3) 28-day control; (4) 28-day
DM; (5) DM treated with insulin; (6) DM treated with TCV-
116. The kidney-to-body weight ratio, glomerular volume, and
proteinuria were estimated. Glomerular hemodynamic changes
were observed using CLSM and renal expression of endothelial
nitric oxide synthase (eNOS), and neuronal nitric oxide syn-
thase (nNOS) was evaluated by immunofluorescence.
Results. The kidney-to-body weight ratio, glomerular volume,
the diameters of afferent arterioles (AA) and efferent arterioles
(EA), erythrocyte velocities within glomeruli, and volume flow
in glomerular capillary loops in four-day DM were significantly
higher than in control rats, and increases were even more pro-
nounced in the 28-day DM. TCV-116 treatment ameliorated
all these findings and significantly decreased proteinuria, but
there was no effect on the blood glucose level. On the other
hand, insulin treatment was followed by normalization of all
these changes induced in DM. Enhanced renal expression of
eNOS in DM was suppressed when treated with either TCV-
116 or insulin, while expression of nNOS was unaltered among
the four groups.
Conclusion. This imaging procedure allowed us to evaluate
glomerular microcirculation in vivo, including the diameters of
AA and EA, erythrocyte velocity, and volume flow. DM signif-
icantly induced glomerular hemodynamic alteration and renal
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hypertrophy. DM treated with either insulin or ARB amelio-
rated these changes. This study shows that progress in imaging
technology promises to make major contributions to revealing
the involvement of hemodynamic changes in glomerular dis-
eases, aiding prognosis and the monitoring of therapeutic ef-
fects, as well.
Diabetic nephropathy is the leading cause of end-stage
renal disease in developed countries [1, 2]. Intrarenal
hemodynamic abnormalities are thought to be the fore-
most factors responsible for the onset and progression of
diabetic nephropathy [3–6]. Both clinically and experi-
mentally, early diabetes is characterized by an increase
in glomerular filtration rate and renal plasma flow [1,
4]. Glomerular hyperfiltration has been shown to result
from elevations in glomerular capillary blood flow and
glomerular capillary hydraulic pressure [7]. The glomeru-
lar microcirculation is considered to be regulated mainly
by alterations in the vascular resistance of AA and EA,
affecting inflow and outflow. There is increasing evidence
that differential activation mechanisms are responsible
for the functional heterogeneity seen between AA and
EA, exemplified by site-specific response to various me-
chanical and vasoactive stimuli [8].
Knowledge of glomerular hemodynamic changes in
vivo is still limited under pathophysiologic conditions.
So far, intravital glomerular hemodynamics have been
evaluated in juxtamedullary nephrons [9–11] and hy-
dronephrotic kidneys [12, 13] using needle-probe, charge-
coupled device (CCD) videomicroscope [14]. However,
these approaches represent invasive manipulations that
might alter the physiologic environment of general and/or
local hemodynamics, particularly at the sensitive level of
the microvasculature, including afferent and efferent ar-
terioles. Recently, we have reported a new technique to
directly visualize the glomerular microcirculation under
physiologic and pathologic conditions, using CLSM in
combination with a high-speed CCD video camera [15].
The present study was undertaken to directly observe the
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alteration of hemodynamics from the early to the late
stages of diabetes in rats. This line of approach provides
us with novel information for clarifying the mechanisms
of progression of diabetic nephropathy resulting from im-
paired microvascular responses to hyperglycemia.
Since the pioneer work of Brenner’s group [16], there
has been accumulating evidence that glomerular hy-
perfiltration and/or hypertension may cause progressive
glomerular injury in the experimental models of dia-
betic nephropathy and 5/6 nephrectomy [17]. Strategies
for preventing the progression of renal failure in pa-
tients with diabetes mellitus include control of blood
glucose level and blood pressure. It has been reported
that blocking the renin-angiotensin system (RAS) slows
the progression of established diabetic nephropathy in
type 1 diabetes mellitus [18–21]. To further elucidate the
role of angiotensin II (Ang II) in renal hemodynamics
in diabetic rats, we examined in vivo the effects of a
selective AT1 receptor antagonist, TCV-116, on renal
hemodynamic changes in diabetic rats.
METHODS
Animals
Studies were performed in male Munich Wistar rats six-
to seven weeks old, purchased from Simonsen Laborato-
ries, Inc. (Day Road, Gilroy, CA, USA). Diabetes were
induced by intraperitoneal injection of STZ (65 mg/kg
body wt) dissolved in 0.1 mol/L sodium citrate buffer, pH
4.5. Blood and urine glucose concentrations were mea-
sured after 24 hours using a reflectance meter (Glucome-
ter Elite; Bayer, Leverkusen, Germany). Diabetic and
control rats were followed-up for four and 28 days. All
rats received standard chow and tap water. Only rats with
blood glucose levels more than 15 mmol/L were included.
To examine the effects of insulin treatment, 24 hours af-
ter the injection of STZ, all rats exhibited blood glucose
concentrations above 15 mmol/L, and insulin treatment
was initiated using nearly 24-hour–acting Humalin N (Eli
Lilly, Kobe, Japan). The dose of insulin was adjusted for
individual animals in the range of 3 to 10 units per rat
so that fasting blood glucose concentrations were kept
112.9 ± 59.8 mg/mL. We also examined in vivo the ef-
fect of treatment with a selective angiotensin II type
1 receptor blocker, TCV-116 (Takeda Chemical Indus-
tries, Tokyo, Japan). Diabetic rats received TCV-116,
5 mg/kg/d, for 28 days starting 24 hours after STZ
injection.
Urine analysis
On days four and 28 after the injection of STZ, the rats
were individually housed in metabolic cages with free
access to water for collection of 24-hour urine specimens.
The amount of urinary protein excreted was determined
by the Biuret method as described previously [22].
Measurement of kidney weight
To measure kidney weight, the bilateral kidneys were
removed and decapsulated. The decapsulated kidneys
were placed in tissue paper for one minute, then trans-
ferred to a scale and weighed.
Isolation of glomeruli
After measurement of kidney weight, the outer 1 to
2 mm of the renal cortex of the left kidney was excised and
cut into fine fragments. The glomeruli were then isolated
in Dulbecco’s modified Eagle’s medium (DMEM) by a
standard sieving technique, as described previously [23].
At each step the tissue was abundantly rinsed. The pH
of the medium was adjusted to 7.4 before use. The whole
procedure for isolation of glomeruli was carried out at
room temperature within 15 minutes of removal.
Measurement of glomerular volume
Isolated glomeruli were allowed to adhere to an obser-
vation chamber coated with poly-L-lysine (1 mg/mL) for
five to 10 seconds. Unattached glomeruli were removed
by gentle washing with fresh isolation medium. Adherent
glomeruli were viewed in a microscope, and then their im-
ages were captured by computer, as described previously
[23]. The area of each glomerulus was automatically mea-
sured using NIH software. The volume of each glomeru-
lus was calculated from the area (S) using the formula
V = 4/3p (S/p )3/2. At least 120 glomeruli from three or
more rats were studied in each experiment.
Intravital observation of the renal microcirculation
Observations of microcirculation blood flow were
made with an intravital microscope system (Nikon,
Tokyo, Japan), equipped with a real-time confocal scan-
ner unit model CSU10 and image processing devices, as
described previously [15]. The scanner actually captures
360 frames of confocal images, which one can observe at
the eyepiece of the scanner, and sends 30 frames of confo-
cal images per second to an ICCD camera (Model C2400-
89; Hamamatsu Photonics K.K., Shizuoka, Japan) to
synchronize with the scanning rate of the camera and be
video-recorded (Model SVO-9600; Sony, Tokyo, Japan)
for later analysis using a recording lens and salt water im-
mersion objectives (Flour 10×/0.30W, Flour 40×/0.80W,
Nikon).
The Munich Wistar rats were anesthetized by in-
traperitoneal injection of thiobutabarbital sodium salt
(100 mg/kg). The body temperature of animals was kept
37.0◦C on a heating pad. Polyethylene catheters (PE50)
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were inserted into the carotid artery for blood pressure
measurements, and into the femoral vein for adminis-
trating labeled plasma components and autologous red
blood cells (RBCs). The left kidney was exposed by a
flank incision and split longitudinally. The prepared kid-
ney was immobilized in a kidney groove to reduce kidney
movement caused by respiration and heartbeat. The kid-
ney was immersed in a bath of physiologic saline (Na+
154 mEq/L, Cl− 154 mEq/L) in which the temperature
was kept at 37 ± 1◦C. Three to five glomeruli were
generally found on the kidney surface. Glomeruli on
the flat portion of the kidney surface were selected for
observation.
Measurement of microhemodynamic parameters
in glomerular tufts
Measurement of vessel diameter. To measure the in-
ner diameter of the glomerular capillary, enhancement of
the contrast of microvessel images against a dark back-
ground was made by intravenous injection (10 mg mL−1,
2 mL kg−1) of a solution of fluorescein isothiocyanate
(FITC)-labeled dextran (FITC-Dx, MW 150,000; Sigma
Chemical Co., St. Louis, MO, USA). This procedure pro-
duced bright fluorescent images of the vascular lumen,
and made the boundary lines of vessels distinctly visible.
Diameters of microvessels were measured with a vernier
caliper on individual frames of the video-recorded im-
ages. Diameters of AA and EA were measured at the
anatomizing portion of their branches entering and leav-
ing glomeruli, respectively. Each value of vessel diameter
was calculated by averaging all measurements obtained,
and represents the mean of 10 to 20 individual determi-
nations.
Erythrocyte velocity. To measure erythrocyte velocity,
a batch of erythrocytes labeled with FITC was injected in-
travenously. Briefly, washed erythrocytes obtained from
an experimental rat were incubated with a phosphate-
buffered saline (PBS) (137 mmol/L NaCl, 6.4 mmol/L
Na2HPO4, 2.7 mmol/L KCl, 1.5 mmol/L KH2PO4, pH
7.8) solution containing 1 mg/mL FITC (ICN Pharma-
ceutical, Inc., Cleveland, OH, USA). The labeled cells
were then washed twice with a saline solution containing
1% bovine serum albumin (BSA; Sigma Chemical Co.)
to remove free dye. The final volume percent of the la-
beled cells was adjusted to approximately 50% by adding
an isotonic saline solution, and an aliquot of these sus-
pensions was injected (1 mL/kg) through the tail vein of
the rat to measure centerline erythrocyte velocity. The
action of the labeled RBC in total RBC was about 1%,
by a single calculation. From the video-recorded images,
erythrocyte velocity was calculated by frame-by-frame
analysis; more than five different areas were measured
and averaged for at least five measurements.
Calculation of volume flow in glomerular capillaries (v)
Volume flow in glomerular capillaries was defined as
the erythrocyte velocity in glomerular capillary (GEV)
and capillary cross-sectional area (calculated from its in-
ner diameter of capillary D): F = GEV×p (D/2)2.
Immunofluorescence
Indirect immunofluorescence for was performed on
3-lm frozen sections as described elsewhere [22]. The
primary antibodies were polyclonal rabbit anti-eNOS an-
tibody (ABR, Inc., Golden, CO, USA) diluted 1:250,
and polyclonal rabbit anti-nNOS antibody (Transduc-
tion Laboratories, Lexington, KY, USA) diluted 1:100.
The secondary antibody was FITC-conjugated mouse
antirabbit-IgG (Santa Cruz Biotechnology, Santa Cruz,
CA, USA).
Statistical analysis
All measured values are given as mean ± standard de-
viation (SD). The nonparametric Mann-Whitney U test
was used for comparison of the measured values of ery-
throcyte velocities because these parameters are known
to have a distribution, which deviates considerably from
the Gaussian. P values less than 0.05 were considered
significant in all statistical tests.
RESULTS
Determination of baseline characteristics
of experimental animals
At four and 28 days after STZ injection, determina-
tion of baseline characteristics revealed significant dif-
ferences between the groups investigated, as shown in
Table 1. Although body weight was less in diabetic rats
at both four and 28 days post injection, diabetic kid-
neys weighed more than control kidneys at both time
points. The kidney-to-body weight ratio in four-day dia-
betic rats was significantly higher than that seen in control
rats, and this difference was even more pronounced in
the 28-day diabetic group. Blood glucose, urine glucose,
and proteinuria were markedly elevated in diabetic ani-
mals. TCV-116 treatment partially reduced the kidney-to-
body weight ratio, and significantly prevented proteinuria
compared with untreated diabetic rats, but there was no
effect on blood glucose level and body weight during
treatment with TCV-116 for four weeks. Insulin treat-
ment for inducing euglycemia significantly decreased the
kidney-to-body weight ratio and proteinuria compared
with untreated diabetic rats. There was no difference
in hematocrit value and mean arterial blood pressure
among four groups (Table 1).
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Table 1. General features of experimental animals
4-day 28-day
Control DM Control DM DM + Insulin DM + TCV-116
N = 14 N = 14 N = 24 N = 27 N = 5 N = 6
Body weight g 151.5 ± 23.2 135.0 ± 14.7 179.0 ± 41.9 122.2 ± 31.9b 169.5 ± 37.6c 121.0 ± 17.1b
Kidney weight mg 1333.2 ± 79.6 1640.5 ± 99.2a 1511.3 ± 127.5 1813.5 ± 250.1b 1458.5 ± 91.3c 1538.6 ± 296.9c
Kidney weight/body weight mg/g 8.8 ± 0.4 12.1 ± 0.5a 8.4 ± 0.5 14.8 ± 0.7b 8.6 ± 0.7c 12.8 ± 2.5b,c
Blood glucose mg/mL 98.8 ± 8.9 371.0 ± 25.0a 102.0 ± 2.6 425.4 ± 107.7b 112.9 ± 59.8c 385.9 ± 292.1b
Urinary glucose g/day 0 10.2 ± 4.0a 0 8.1 ± 2.9b 0.3 ± 0.4 c 8.2 ± 0.6b
Proteinuria mg/day 2.2 ± 2.1 10.7 ± 5.6a 2.4 ± 1.7 37.9 ± 15.9b 3.8 ± 2.0c 9.3 ± 6.6b,c
Hematocrit % 48.6 ± 3.3 48.5 ± 1.9 48.0 ± 1.6 48.4 ± 1.7 48.2 ± 2.0 48.1 ± 1.8
Mean arterial pressure mm Hg 106.1 ± 4.3 107.0 ± 3.1 105.0 ± 7.0 101.0 ± 8.5 100.5 ± 8.6 99.0 ± 7.9
N, number of rats were observed in each group.
aP < 0.05, vs. 4-day control rats.
bP < 0.05, vs. 28-day control rats.
cP < 0.05, vs. 28-day DM rats.
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Fig. 1. Glomerular volume in different groups. , Control, , DM,
DM + Ins, DM + ARB. All results were expressed as mean ± SD.
∗P < 0.01 vs. 4-day control, #P < 0.01 vs. 28-day control, +P < 0.01 vs.
28-day DM.
Measurement of glomerular volume
Using isolated glomeruli from diabetic and control
groups, we directly observed glomerular size and calcu-
lated the volume of glomeruli. We demonstrated that the
volume of glomeruli was markedly larger in four-day dia-
betic rats as compared with control rats, and much larger
in the 28-day diabetic group. TCV-116 treatment largely
decreased glomerular volume compared with untreated
diabetic rats, but still more than control rats. Insulin treat-
ment resulted in a near normalization of glomerular vol-
ume compared with control rats (Fig. 1), as described
previously [24, 25].
The effect of diabetes on diameters of AA, EA,
and ratio of AA to EA (AA/EA)
The left kidneys of Munich Wistar rats were observed
by intravital microscopy. Figures 2 and 3 show the typical
images of AA and EA in control (Fig. 2A and B) and
diabetic rats (Fig. 3A and B) of 28-day group. The affer-
ent and/or efferent arterioles were identified by obser-
vation of the microvascular branches and the direction
of movement of labeled red blood cells. Table 2 shows
the difference in diameters of AA, EA, and AA/EA be-
tween diabetic and control groups. On day four after STZ
injection the diameters of AA in diabetic rats (11. 75 ±
1. 28 lm) were significantly increased compared to con-
trol rats (8.88 ± 0.54 lm). In addition, the diameters
of EA in diabetic rats (11.0 ± 1.79 lm) were also sig-
nificantly increased when compared with control rats
(8.44 ± 0.71 lm). Furthermore, we showed that the
AA/EA ratio was slightly increased in diabetic rats at four
days. On day 28 after STZ injection, the diameters of AA
in diabetic rats (12.32 ± 0.84 lm) were enlarged further,
significantly greater than in controls (9.36 ± 1.28 lm). In
contrast, the diameters of EA in diabetic rats (11.05 ±
1.17 lm) did not increase further, although there was sig-
nificant difference to controls (8.78 ± 1.01 lm). More-
over, AA/EA ratios in diabetic groups were obviously
increased when compared with control and day four dia-
betic groups, indicating a continuous increase in internal
glomerular pressure with time.
The effect of diabetes on renal erythrocyte velocity
We observed and measured the erythrocyte velocities
in control and diabetic groups. Figures 2 and 3 also show
the typical images of erythrocyte velocity in the glomeru-
lar tufts in control (Fig. 2C and D) and diabetic rats
(Fig. 3C and D) of the 28-day group. On day four af-
ter STZ injection, erythrocyte velocities within glomeruli
(GEV) were slightly higher in diabetic rats (991.4 ±
158.6 lm/sec) than in control rats (802.0 ± 172.9 lm/sec)
(Fig. 4). Similarly, erythrocyte velocities within the mi-
crovasculature around the Bowman’s capsule (BEV)
were also slightly higher in diabetic rats (624.4 ± 223.8
lm/sec) than in control rats (463.7 ± 190.4 lm/sec)
(Fig. 5). On day 28 after STZ injection, GEV was
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Fig. 2. Representative images showing movement of RBC in glomerular microvasculature, AA, and EA from control of 28-day groups. To measure
vessel diameter and erythrocyte velocity, rats were injected with FITC-labeled dextran and red blood cells. Arrowheads in (A) and (B) show AA
and EA, respectively. Arrowheads in (C) and (D) show the sequence of RBC flow during 0.04 seconds. The average value of RBC velocity within
the glomerular tufts in control group was 823.1 ± 176.3 lm/second (bars, 10 lm).
significantly higher in diabetic rats (1129.8 ± 233.2
lm/sec) than in control rats (823.1 ± 176.3 lm/sec) (Fig.
4). On day 28, BEV was also markedly higher in diabetic
rats (683.0 ± 141.8 lm/sec) than in control rats (495.9 ±
134.8 lm/sec), as shown in Figure 5. Treatment with TCV-
116 significantly reduced GEV compared with untreated
diabetic rats. On the other hand, insulin treatment pre-
vented this change induced by diabetes (Fig. 4).
The effect of diabetes on volume flow in glomerular
capillaries
In order to estimate the degree of overloading of
glomerular blood flow in diabetes, we calculated the
change of volume flow in glomerular capillaries using the
equation V = GEV × p (D/2)2. Volume flow in four-day
diabetic rats was 50% greater than in controls, and it was
even more pronounced in the 28-day diabetic group, be-
ing about 80% greater than in controls (Fig. 6). Treatment
with TCV-116 significantly decreased volume flow in sin-
gle glomerular capillary loops compared with untreated
diabetic rats. Insulin treatment prevented this alteration
induced by diabetes (Fig. 6).
Immunofluorescent findings for eNOS and nNOS
In order to examine the involvement of eNOS and
nNOS in glomerular hyperperfusion in experimental dia-
betic rats, as indicated previously [1, 12, 26], we estimated
semiquantitatively the expression of eNOS and nNOS in
four experimental groups by immunofluorescence. Ex-
pression of eNOS in glomeruli appeared to be enhanced
in DM groups compared with normal controls, but this in-
creased expression was reduced by treatment with either
insulin or TCV-116 (Fig. 7). Immunofluorescence studies
showed a prominent expression of nNOS in the macula
densa, and this expression was similar among the four
groups (Fig. 8).
DISCUSSION
In the present study, we evaluated the glomerular mi-
crocirculation in diabetic rats in vivo by an intravital
real-time CLSM system, which we first introduced [15].
Using this system, we not only visualized AA, EA, and
the movement of labeled-RBCs within glomeruli and
microvessels around Bowman’s capsule, but could also
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Fig. 3. Representative images showing movement of RBC in glomerular microvasculature, AA, and EA from diabetic rats of 28-day group. Shown
is a typical feature of a glomerulus from a DM rat of 28-day group. Labeled RBC flow into three different branches from the same thick vessel,
shown as a typical afferent arteriole (A). Branching capillaries join into a thick vessel, judged to be an efferent arteriole (B). The average diameter
of AA and EA in 4-week DM group was 12.32 ± 0.84 lm and 11.05 ± 1.17 lm, respectively. Arrowheads in (A) and (C) show the starting point.
Arrowheads in (B) and (D) show the end point. The average value of RBC velocity within the glomerular tufts in the diabetic group was 1129.8 ±
233.2 lm/second (bars, 10 lm).
Table 2. Comparison of AA, EA, and AA/EA between control and diabetic groups
4-day 28-day
Control Diabetes Control Diabetes
AA lm 8.88 ± 0.54 (N = 6) 11.75 ± 1.28a (N = 6) 9.36 ± 1.28 (N = 14) 12.32 ± 0.84b (N = 14)
EA lm 8.44 ± 0.71 (N = 5) 11.0 ± 1.79a (N = 4) 8.78 ± 1.01 (N = 10) 11.05 ± 1.17b (N = 12)
AA/EA 1.05 1.07 1.06 1.11
N, number of AA or EA was observed in each group.
aP < 0.05, vs. 4-day control rats.
bP < 0.05, vs. 28-day control rats.
calculate GEV, BEV, and volume flow in single glomeru-
lar capillaries. Enlargement of the kidney, the altered di-
ameters of afferent arterioles and efferent arterioles, and
increased GEV, BEV, and volume flow in single glomeru-
lar capillaries in diabetic rats, as described previously [6,
12, 27], have been reconfirmed. In addition, renal ex-
pression of eNOS was enhanced in DM. TCV-116 treat-
ment ameliorated glomerular hemodynamic alterations
and renal hypertrophy, decreased significantly protein-
uria, and reduced the expression of eNOS, compared with
untreated diabetic rats. In addition, TCV-116 administra-
tion to control rats didn’t effect glomerular hemodynamic
alterations and renal hypertrophy (data not shown). ARB
seems to be effective in preventing both renal damage
and progression of diabetic nephropathy. On the other
hand, insulin treatment for glycemic control was fol-
lowed by normalization of renal growth and glomeru-
lar microcirculation, and by suppression of proteinuria,
indicating that hyperglycemia, but not STZ itself, induced
alterations in glomerular hemodynamics and proteinuria.
These results support the view that a very early interven-
tion with strict insulin treatment can completely reverse
the renal structural and hemodynamic changes in exper-
imental diabetes.
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Fig. 4. Erythrocyte velocities within glomeruli in different groups. ,
Control, , DM, DM + Ins, DM + ARB. All results were expressed
as mean ± SD. ∗P < 0.01 vs. 4-day control, #P < 0.01 vs. 28-day control,
+P < 0.01 vs. 28-day DM.
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Fig. 5. Erythrocyte velocities in the microvasculature around Bow-
man’s capsule in diabetic and control groups. , Control, , DM. All
results were expressed as mean ± SD. ∗P < 0.01 vs. 4-day control, #P <
0.01 vs. 28-day control.
A previous study employing video microscopy re-
ported appreciable dilatation, predominantly in the af-
ferent arteries and to a much lesser degree in the efferent
arteries, results similar to our own, although hemody-
namic changes of renal microvessels were quantitative
in hydronephrotic kidneys of diabetic rats [28]. Invasive
methods using fiberscope or hydronephrotic model of
unilateral ureter ligation may themselves cause fluctu-
ation of the hemodynamics in response to the external
stimuli given. In reality, hydronephrosis is accompanied
by a marked decrease in kidney blood flow [29, 30]. The
CLSM intravital videomicroscopic technique appears to
better other methodologic approaches in the following
points First, this technique avoids nonphysiologic effects
of invasive operative procedures. Second, this system of-
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Fig. 6. Volume flow in glomerular capillaries in different groups. ,
Control, , DM, , DM + Ins, DM + ARB. All results were expressed
as mean ± SD. ∗P < 0.01 vs. 4-day control, #P < 0.01 vs. 28-day control,
+P < 0.01 vs. 28-day DM.
fers real-time observation and recording of continuous
images of movement of FITC-labeled RBCs, and cal-
culation of the erythrocyte velocities within glomeruli
and microvessels around Bowman’s capsule. This sys-
tem can, in fact, capture 360 frames of confocal images,
and send 30 frames of confocal images per second to
an ICCD camera. Third, the diameters of afferent ar-
terioles, efferent arterioles, and glomerular blood flow
can be evaluated. Fourth, systemic hemodynamics (e.g.,
blood pressure) can be measured simultaneously. Fifth,
the technique and experimental preparation are simpler
than other approaches for direct visualization of the renal
microcirculation.
Although body weight was less in the diabetic rats, dia-
betic kidneys weighed 22% more than control kidneys
in the four-day group. There is a higher ratio of kid-
ney/body weight in four-day groups that was even more
pronounced in the 28-day group. Glomerular volume sig-
nificantly increased with length of disease, reaching about
double on day 28. Kidney weight, well known to be a
strong predictor of glomerular filtration [6], is affected
by glomerular blood flow velocity and flow rate. As indi-
cated here, glomerular blood flow velocity was already
significantly increased on day four, with a further ad-
ditional increase on day 28. In contrast, the blood flow
velocity in the microvasculature around Bowman’s cap-
sule was slightly, but significantly increased in diabetic
rats compared to control rats, while there appeared to be
no change from the early to the late phase of diabetes.
Overloading of glomerular blood flow in diabetes was
also confirmed by measuring the diameters of afferent
and efferent arterioles, and estimating glomerular blood
flow rate. The net result of the increase of ratio between
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Fig. 7. Immunofluorescence staining of
eNOS in cryostat kidney sections at day 28.
The glomeruli from control rats showed faint
staining for eNOS (A). In untreated DM rats,
the glomeruli revealed enhanced expression
of eNOS compared with control rats (B).
Insulin treatment attenuated intraglomerular
expression of eNOS compared with untreated
DM rats (C). Treated with ARB rats also
inhibited intraglomerular expression of
eNOS compared with untreated DM rats
(D).
Fig. 8. Immunofluorescence staining of
nNOS in cryostat kidney sections at day 28.
Positive staining for nNOS was observed in
the macula densa. Kidney section of control
rats (A). Kidney section of DM rats without
treatment (B). Kidney section of DM rats
treated with insulin (C), or with ARB (D).
There was no apparent difference in staining
intensity of nNOS among the four groups.
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the diameters of afferent and efferent arteries is that the
enhanced glomerular blood flow was permitted to enter
the glomerulus, leading to glomerular hyperperfusion on
28 day of diabetes, by about 80% more than in controls.
In the present study, we observed that the diameters
of afferent and efferent arterioles were significantly in-
creased in diabetic rats at four and 28 days compared with
control rats. Actually, basal diameters of all vessel types
were wider in diabetic rats than in control rats (data not
shown), consistent with a previous study [12]. Further-
more, the diameters of AA further enlarged with time,
while the diameters of EA on day 28 were not different
to those on day four. Diabetic rats showed a reduced re-
nal vascular resistance, which may have been caused by
increased NO production in the renal microcirculation
[1, 12, 31–33]. Increase of AA and EA diameters might
be considered a compensative mechanism in diabetes to
buffer glomerular hyperperfusion and hypertension. But
the compensative capacity of EA was lower than AA.
These results indicated different characteristics of dila-
tory functions between AA and EA, under high glucose
condition. The AA/EA ratio is thought to be an important
indicator of changes in the glomerular microcirculation.
When systemic blood pressure is constant, an increase in
the AA/EA ratio increases internal glomerular pressure,
whereas a decrease lowers it. In the present study, we
showed that the AA/EA ratio was slightly increased in di-
abetic rats at four days, and thereafter, further increased
at day 28, indicating sustained glomerular hypertension.
Both high glucose and hypertension could induce en-
dothelial cell dysfunction, which represents a common
pathophysiologic pathway of diabetic complications [34–
36]. Endothelial cells not only produce vasodilation me-
diators, NO, but also vasoconstriction mediators, includ-
ing endothelin, and Ang II, regulating vascular tone by
maintaining a balance between vasodilation and vasocon-
striction [34]. There is increasing evidence that ARBs are
significantly effective in protecting against the progres-
sion of diabetic nephropathy, not only in terms of an-
tihypertensive effect, but also by renoprotective action,
independent of its blood pressure–lowering effect [18].
In fact, ARBs could reduce oxidative stress and improve
nitric oxide bioavailability [37]. In addition, ARBs could
lower the glomerular filtration rate and filtration fraction,
and improve glucose oxidation in type 1 diabetes [38]. Re-
cently, enhanced oxidative stress and eNOS of expression
in the aorta have been demonstrated in the early stage in
diabetic rats [39]. Our recent study also showed that high
glucose could induce increased eNOS protein expression,
but decreased NO release in human glomerular endothe-
lial cells, suggesting disturbed NO bioavailability, and that
it was corrected by SOD [40]. Furthermore, angiotensin
II stimulated the activity and expression of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase [41,
42], whose product, a superoxide anion, can react with
NO to form peroxynitrite. Welch et al demonstrated that
ARB corrected oxidase stress and restored nitric oxide
signaling in the juxtaglomerular apparatus [43]. Many
studies have shown evidence that increased eNOS ex-
pression involved glomerular hemodynamic changes in
early diabetic nephropathy [1, 33]. In the present study,
we demonstrated that expression of eNOS in glomeruli of
DM rats appeared more prominent than in those of con-
trol rats, consistent with other previous studies [1, 20, 33,
39]. On the other hand, we could not confirm an increase
in nNOS expression in the kidney of STZ-induced dia-
betic rats, consistent with a previous study [20]. There are
conflicting reports in which nNOS expression was shown
to increase [26, 44] or decrease [45, 46] in the kidney of
diabetic rats. This discrepancy may be explained by the
severity of diabetes and the degree of hyperglycemia in-
duced. In conclusion, the molecular mechanisms initially
causing glomerular hypertension and hyperperfusion in
diabetic nephropathy, as well as those by which ARBs
protect against progression, still remain undefined.
An imaging procedure, CLSM in combination with
a high-speed video camera, allowed us to evaluate
glomerular microcirculation in vivo, including the diam-
eters of AA and EA, erythrocyte velocity, and volume
flow. DM induced significantly glomerular hemodynamic
alteration and renal hypertrophy.
Furthermore, we could monitor glomerular hemo-
dynamic changes to examine the therapeutic effect of
insulin or ARB in DM. As a result, we know that
these treatments are able to ameliorate pathologic
changes induced in DM by normalization of glomerular
hemodynamics. Further progress in imaging technology,
including exotic modalities in combination with novel in-
dicator probes, promises to contribute to revealing the
pathologic involvement of hemodynamic changes at the
cellular and molecular levels, as well as helping to de-
termine prognosis and therapeutic effects in progressive
glomerular diseases.
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